Ken Griffin Keros Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $445,608 - $761,184	10,800 Added 720.0%	12,300 $814,000
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $24,408 - $36,945	900 Added 150.0%	1,500 $59,000
Q2 2023 Aug 14, 2023	SELL	$37.26 - $51.01 $14,904 - $20,404	-400 Reduced 40.0%	600 $24,000
Q1 2023 May 15, 2023	SELL	$41.44 - $59.32 $721,056 - $1.03 Million	-17,400 Reduced 94.57%	1,000 $42,000
Q4 2022 Feb 14, 2023	SELL	$39.45 - $51.77 $291,930 - $383,098	-7,400 Reduced 28.68%	18,400 $883,000

Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $230,740 - $332,996	8,300 Added 47.43%	25,800 $971,000

153

26.7M

47.6K

34.5K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.